Exhibit 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

On June 24, 2013, Cynosure, Inc. (“Cynosure”) completed its acquisition of Palomar Medical Technologies, Inc., (“Palomar”), pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of May 15, 2013 (the “Merger Agreement”), by and among Cynosure, a Delaware corporation, Commander Acquisition, LLC (formerly Commander Acquisition Corp.), a Delaware limited liability company and wholly-owned subsidiary of Cynosure (the “Merger Sub”), and Palomar, a Delaware corporation. As a result of the transaction, former Palomar stockholders, in the aggregate, received $145.8 million in cash and 6.0 million shares of Cynosure Class A common stock for their shares of Palomar common stock. The total consideration was valued at $287.2 million, based upon the closing price of Cynosure Class A common stock on June 24, 2013.

Palomar developed innovative aesthetic light-based systems for hair removal and other cosmetic procedures, including both lasers and high powered lamps. The acquired aesthetic laser assets include Icon Aesthetic System, the StarLux laser and pulsed light system and the Vectus diode laser.

The acquisition complements and broadens Cynosure’s product lineup with the addition of Palomar’s intense pulsed light, fractional laser and diode aesthetic systems, doubles the number of patents in Cynosure’s portfolio and enhances Cynosure’s global distribution network.

During the integration process Cynosure identified reliability issues with Palomar’s Vectus diode laser, primarily involving the large tip delivery system. Cynosure is currently reviewing shipments to new customers while they address these issues. Demand for the Vectus diode laser remains high and Cynosure is working to resolve these issues and support customers in the coming quarters.

The unaudited pro forma condensed combined financial information that follows combines the historical accounts of Cynosure and Palomar. The unaudited pro forma condensed combined balance sheet as of March 31, 2013 shows the consolidated financial position of Cynosure and Palomar as if the merger had occurred on that date. The unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2013 and the year ended December 31, 2012 reflect the companies’ consolidated results as if the merger had occurred as of January 1, 2012. The historical consolidated financial information has been adjusted to reflect factually supportable items that are directly attributable to the merger, and with respect to the unaudited pro forma condensed combined statements of operations only, are expected to have a continuing impact on consolidated results of operations.

This pro forma financial information should be read in conjunction with:

The unaudited pro forma condensed combined financial information has been prepared for illustrative purposes only, and is based on estimates using information available at this time. You should not rely on this information as being indicative of future consolidated results or the future financial position after the acquisition. The determination of the final allocation of the purchase price has not been completed as Cynosure continues to determine the fair value of certain assets and liabilities acquired and has retained an independent valuation firm to assist with the determination of the fair value of certain assets acquired. Accordingly, the purchase accounting adjustments made in the preparation of the unaudited pro forma condensed combined financial information are preliminary and subject to adjustment. Such adjustments may be material. The unaudited pro forma condensed combined financial information does not give consideration to the impact of possible revenue enhancements, expense efficiencies, strategy modifications, asset dispositions or other actions that may result from the integration of Cynosure’s and Palomar’s operations.

The unaudited pro forma condensed combined financial information has been prepared using the acquisition method of accounting with Cynosure treated as the accounting acquirer. Accordingly, the assets, liabilities and commitments of Palomar, the accounting acquiree, are adjusted to their estimated March 31, 2013 fair values. The estimates of fair value are preliminary and are dependent upon certain valuations and other studies that have not progressed to a stage where there is sufficient information to make a definitive valuation.

CYNOSURE, INC.

Unaudited Pro Forma Condensed Combined Balance Sheet

As of March 31, 2013

(In thousands)

CYNOSURE, INC.

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Three Months ended March 31, 2013

(In thousands, except per share amounts)

CYNOSURE, INC.

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Fiscal Year ended December 31, 2012

(In thousands, except per share amounts)

Notes to Unaudited Pro Forma Condensed Combined Financial Statements

Note 1. Basis of Presentation

On June 24, 2013, Cynosure completed its acquisition of Palomar. The accompanying unaudited pro forma condensed combined financial statements present the pro forma condensed combined financial position and results of operations of the combined company based upon the historical financial statements of Cynosure and Palomar, after giving effect to the merger and adjustments described in these notes, and are intended to reflect the impact of the merger on Cynosure.

The accompanying unaudited pro forma condensed combined financial statements are presented for illustrative purposes only and do not give effect to any cost savings, revenue synergies or restructuring costs that may result from the integration of Cynosure’s and Palomar’s operations.

The unaudited pro forma condensed combined balance sheet reflects the merger as if it was completed on March 31, 2013 and includes pro forma adjustments for Cynosure’s preliminary valuations of certain tangible and intangible assets. These adjustments are subject to further adjustment as additional information becomes available and additional analyses are performed. The unaudited pro forma condensed combined statements of operations reflect the merger as if it had been completed on January 1, 2012.

The pro forma condensed combined balance sheet has been adjusted to reflect the allocation of the purchase price to identifiable net assets acquired. The purchase price allocation included within these unaudited pro forma condensed combined financial statements is based upon the purchase price of $287.2 million. This amount reflects the conversion of each outstanding share of Palomar common stock (including the issuance of common stock upon the conversion of restricted stock units and stock appreciation rights and upon the exercise of outstanding stock options) into the right to receive $6.825 in cash and 0.2819 shares of Cynosure Class A common stock. Cynosure issued approximately 6.0 million shares of Class A common stock based on a calculated exchange ratio of 0.2819, which is the exchange ratio calculated as of June 24, 2013, the effective date of the merger. Any Palomar stock options that were not exercised prior to the acquisition were cancelled.

The following is a summary of the purchase price for Palomar:

For purposes of this pro forma analysis, the above purchase price has been allocated based on an estimate of the fair value of net assets acquired.

For purposes of the unaudited pro forma condensed combined financial statements, the estimated allocation to acquired identifiable intangible assets is expected to be within (but not limited to) the following general categories:

The unaudited pro forma condensed combined financial statements include estimated identifiable intangible assets with a fair value aggregating $40.3 million, which will be amortized based on the pattern in which the economic benefits of the respective intangible assets are consumed. If no such pattern can be reliably determined, straight-line amortization will be followed. The current estimated weighted average life approximates 15 years. Independent valuation advisors are being used to assist with the estimate of the identifiable intangible asset value. The estimated identifiable intangible asset value is primarily based on information and assumptions developed by Cynosure management, certain publicly available information, and discussions with Palomar’s management. These estimates will be adjusted based upon the final valuation and any such adjustments could be significant. The final valuation is expected to be completed within 12 months after the completion of the merger.

In accordance with the requirements of ASC 350—Intangibles—Goodwill and Other, any goodwill and acquired indefinite-lived intangible assets associated with the merger will not be amortized.

Based on the purchase price, the estimated net fair value of the assets acquired was less than the purchase consideration. Consequently, the initial purchase price allocation resulted in goodwill of $105.3 million.

Upon completion of the fair value assessment after the merger, Cynosure anticipates that the ultimate purchase price allocation will differ from the preliminary assessment outlined above. Any changes to the initial estimates of the fair value of the assets and liabilities will be recorded as adjustments to those assets and liabilities and residual amounts will be allocated to goodwill. Any such adjustment to goodwill could be significant.

Note 2. Pro Forma Adjustments (amounts in thousands unless otherwise noted)

Pro forma amortization expense for all of the identifiable intangible assets acquired was recorded based on the pattern in which the economic benefits of the intangible assets are consumed. The current estimate is a weighted average life approximating 15 years.

Amortization expense (including amortization recognized within cost of revenues), based on the pattern in which the economic benefits of the intangible assets are consumed, for each of the succeeding five years and thereafter at December 31, 2012, would approximate:

The merger between the companies is expected to result in carryover basis for all tax attributes. As a result, the Company recorded a net deferred tax liability of approximately $5.5 million. This amount represents: the net deferred tax assets acquired from Palomar of $36 million offset by the $18.1 million of deferred tax liabilities recorded in acquisition accounting (primarily associated with the basis difference in the acquired intangible assets) and a valuation allowance established in purchase price

accounting of $23.4 million. Cynosure has considered the deferred tax liabilities as sources of income to support the partial realization of the legacy U.S. deferred tax assets of Cynosure. As a result, during the quarter ended June 30, 2013, Cynosure recorded an income tax benefit of $5.8 million for the release of a portion of the legacy Cynosure domestic valuation allowance. As this was considered nonrecurring, it has not been presented as an adjustment within either the unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31, 2012 or for the three months ended March 31, 2013. However, this benefit is reflected as an adjustment to decrease the pro forma accumulated deficit presented in the unaudited pro forma balance sheet as of March 31, 2013. Cynosure continues to maintain a valuation allowance against its remaining U.S. deferred tax assets and the U.S. deferred tax assets acquired from Palomar. If, due to a restrictive Section 382 limitation or other information that becomes available during acquisition accounting, Cynosure determines that an additional portion of the Cynosure U.S. deferred tax assets are more-likely-than-not realizable, the benefit for the release of any valuation allowance maintained against legacy Cynosure deferred tax assets would be recorded as a tax benefit within net income. Cynosure also continues to maintain a full valuation allowance against its net deferred tax assets in certain foreign jurisdictions including those foreign net deferred tax assets acquired through this merger.

Additional Paid in Capital—Adjustment to eliminate the historical additional paid in capital of $222.0 million of Palomar, offset by an increase of $141.4 million for the issuance of 6,028,105 shares of Cynosure Class A common stock.